IGM Biosciences, Inc.
DelistedCIK 1496323fmd_0F1Y9BTX8JY6KADKJ9VNFZV08JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Jun 30, 2025, 31 periods
Latest annual · FY2024
Millions- Operating income
- (209)
- Net income
- (196)
- Free cash flow
- (159)
Latest quarter · Q2 FY2025
Millions- Operating income
- 96
- Net income
- 98
- Free cash flow
- (51)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
IGM Biosciences, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$208.6 million | -$263.5 million | 10-K 2025-03-06 · proof | |
| Net income | -$195.8 million | -$246.4 million | 10-K 2025-03-06 · proof | |
| Cash from operating activities | -$153 million | -$192.2 million | 10-K 2025-03-06 · proof | |
| Free cash flow | -$158.8 million | -$204.6 million | 10-K 2025-03-06 · proof | |
| Total assets | $265.7 million | $423.4 million | -37.2% | 10-K 2025-03-06 · proof |
| Total liabilities | $217.5 million | $220.2 million | -1.2% | 10-K 2025-03-06 · proof |
| Cash and cash equivalents | $26.5 million | $112.5 million | -76.5% | 10-K 2025-03-06 · proof |
- What was IGM Biosciences, Inc.'s operating income in fiscal 2024?
- IGM Biosciences, Inc. reported operating income of -$208.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -$263.5 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was IGM Biosciences, Inc.'s net income in fiscal 2024?
- IGM Biosciences, Inc. reported net income of -$195.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$246.4 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was IGM Biosciences, Inc.'s cash from operating activities in fiscal 2024?
- IGM Biosciences, Inc. reported cash from operating activities of -$153 million for fiscal 2024 (the year ended Dec 31, 2024), against -$192.2 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What was IGM Biosciences, Inc.'s free cash flow in fiscal 2024?
- IGM Biosciences, Inc. reported free cash flow of -$158.8 million for fiscal 2024 (the year ended Dec 31, 2024), against -$204.6 million the year before. Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are IGM Biosciences, Inc.'s total assets?
- As of Dec 31, 2024, IGM Biosciences, Inc. reported total assets of $265.7 million, against $423.4 million a year earlier (-37.2%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are IGM Biosciences, Inc.'s total liabilities?
- As of Dec 31, 2024, IGM Biosciences, Inc. reported total liabilities of $217.5 million, against $220.2 million a year earlier (-1.2%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
- What are IGM Biosciences, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, IGM Biosciences, Inc. reported cash and cash equivalents of $26.5 million, against $112.5 million a year earlier (-76.5%). Source: the 10-K filed with the SEC on Mar 6, 2025. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1496323&period_type=annual&limit=5"Information only, not investment advice.